we are
ROSWELL PARK
2023
ONE TEAM. ONE VISION.
ROSWELL PARK
COMPREHENSIVE CANCER CENTER
Founded in 1898, Roswell Park Comprehensive Cancer Center was the first institution in the world to focus exclusively on cancer research. Eminent surgeon, Dr. Roswell Park, sought to create a powerful force against cancer by bringing together the knowledge and skills of pathologists, chemists, biologists, surgeons and other experts—all in one center.

That vision has fueled more than a century’s worth of medical discoveries and breakthroughs. Among the first to be designated a comprehensive cancer center by the National Cancer Institute, we pioneered the standard for today’s multidisciplinary approach to cancer care, scientific research and the development of new therapies and technologies.

Today, we set ourselves apart as a leader in transplant and cellular therapies, personalized medicine, cancer vaccines, immunotherapy and robotic surgery.

FOR 125 YEARS, we have remained steadfast to the revolutionary vision of our founder—Dr. Roswell Park—who set out to understand cancer, discover ways to treat it and put an end to the suffering it causes.

Roswell Park, the NATION’S First CANCER CENTER

FOR 125 YEARS, we have remained steadfast to the revolutionary vision of our founder—Dr. Roswell Park—who set out to understand cancer, discover ways to treat it and put an end to the suffering it causes.

KEY DISTINCTIONS

Among a select group of comprehensive cancer centers in the nation DESIGNATED BY THE NATIONAL CANCER INSTITUTE (NCI).

A member of the NATIONAL COMPREHENSIVE CANCER NETWORK (NCCN), a prestigious alliance of leading cancer centers that seeks continuous quality improvement and creates evidence-based practice guidelines.

A LEADER IN CANCER RESEARCH where the latest therapies are available to patients through our robust clinical trials program.

Historical Firsts

1898
Roswell Park Opens
Dr. Roswell Park opens America’s first cancer center.

1904
Chemotherapy Research
Established world’s first chemotherapy research program.

1938
Lung Cancer’s Link to Smoking
Two patients identified as smoking-related cases bring lung cancer’s first smoking link to world attention.

1978
Photodynamic Therapy (PDT)
Photodynamic Therapy (PDT), which combines laser light with light-sensitizing drugs, is FDA-approved.

1975
Pioneered the prostate specific antigen (PSA) test

1985
Two-gene T-cell Engineering
World’s first clinical trial using two-gene combination for T-cell engineering.

1998
Molecular Genetics Project
The world’s first use of microarray technology.

2003
Immunotherapy Breakthroughs
Dr. Robert Schadler, pioneering immunotherapy trials and starting the field of immunotherapy.

2017
First U.S.-Cuba Biotech Venture
Formed the world’s first U.S.-Cuba biotech venture to advance new cancer drugs.

2018
Fiscal Year 2023
We are one of America’s top cancer centers, with 4,188 employees, 5,258 hospital admissions, 294,489 outpatient visits, and 49,105 patients under active care. We serve patients from 42 U.S. states and 1 foreign country, and have 42 hospital beds with an average length of stay of 8.33 days.

FOR 125 YEARS, we have remained steadfast to the revolutionary vision of our founder—Dr. Roswell Park—who set out to understand cancer, discover ways to treat it and put an end to the suffering it causes.
At Roswell Park, we treat the whole patient, not just their cancer. An array of allied clinical and supportive services are integrated into every patient’s personalized care plan, and may include:

- Nutrition
- Rehabilitation therapy
- Lymphedema care
- Pain and palliative care
- Dentistry and maxillofacial prosthetics
- Plastic and reconstructive surgery
- Genetic testing and counseling
- Psychosocial services
- Fertility preservation

Access to Clinical Trials
When you or a loved one has cancer, you need the latest, most promising treatment today. Enrolling in a clinical trial offers earliest access to the newest treatment approaches, drugs and other options, months or even years before they become widely available. Our robust portfolio of clinical trials offers patients access to more options for treatment and hope.

As many as 50% of Roswell Park Patients are Eligible for a Clinical Trial
Roswell Park currently has 300+ Clinical Trials Enrolling Patients

Pioneering Cellular Therapies
Recent breakthroughs in the field of immunotherapy find Roswell Park uniquely poised to expand and accelerate our ability to bring game-changing cellular therapies to the patients who need them. Cell therapies are created for each individual patient, using their own immune T cells, a process that requires sophisticated cell engineering and production facilities. Roswell Park has six of these facilities, so-called clean rooms for cell manufacturing, and is building another 14 to meet the growing need for these therapies that are transforming care for many patients with difficult subtypes of leukemia, lymphoma, multiple myeloma and more.

We already offer patients the latest approved options in T-cell therapies, such as chimeric antigen receptor (CAR) T-cell therapy and more, such as tumor infiltrating lymphocytes (TIL) therapy, are on the horizon or in clinical trials.

Expanding Theranostics
Theranostics is a rapidly growing front in the fight against cancer. This approach uses the latest methods and tools of diagnostic testing to discover features of a person’s cancer that make it treatable with new radiopharmaceuticals. Roswell Park is building a new Theranostics Center to expand the number of patients we can serve with these innovative, outpatient treatments.
Major Research Programs
Just as our clinical care teams include physicians from multiple medical disciplines, faculty from across our clinical and scientific departments collaborate in these multidisciplinary research programs:

- Cancer Stress Biology
- Developmental Therapeutics
- Population Sciences
- Tumor Immunology and Immunotherapy

Shared Resources
Our faculty have access to more than 20 specialized research support laboratories with cutting-edge technology, including:

- Genomics
- Flow & Image Cytometry
- Bioinformatics
- Data Bank and BioRepository
- Pathology Network Shared Resource
- Bioanalytics, Metabolomics and Pharmacokinetics


With more than a century of groundbreaking research, Roswell Park commits intellectual capital and necessary resources to convert scientific discoveries into real-world products and applications, bringing novel therapies to more patients sooner.

Today, Roswell Park drives innovative cancer research in genetics, cell stress and immunotherapy, leading to new personalized treatments.

RESEARCH AT OUR CENTER HAS LED TO:

- **14 BIOTECH SPINOFF COMPANIES** and affiliates to share our discoveries with the world
- **STRATEGIC PARTNERSHIPS** with investigators and centers around the world
- **A CLINICAL RESEARCH CENTER**, specifically for our investigator-initiated phase I clinical trials program
- **FIRST-EVER U.S. CLINICAL TRIALS** of Cimavax, a lung cancer immunotherapy developed in Cuba.

- **$104.2M** GRANTS/CONTRACTS (per annum)
- **493** FUNDED RESEARCH PROJECTS
- **121** LICENSE AGREEMENTS
- **91** U.S. PATENTS
Roswell Park’s education mission is multifaceted, aimed at reducing the global cancer burden in these specific ways:

Training the next generation of cancer experts
With world-renowned faculty and alliances with local and regional high schools, colleges and universities, Roswell Park provides specialized training, education and certification programs in several oncology and related fields:

- Clinical training of residents and fellows
- Predoctoral, master’s and postdoctoral training in basic and translational cancer biology
- Advanced training in oncology nursing
- Continuing medical education for physicians and dentists
- Cancer prevention for the general public

> Allied health baccalaureate and professional training
> Public and professional education about cancer and HIV/AIDS
> Ethics in basic and clinical research
> Summer research experiences for high school, college and medical students

Since its inception in 1991, over $575 million have been raised for cancer research grants and patient care programs.

The Alliance Foundation is a 501(c)(3) not-for-profit organization that manages all donations made to Roswell Park Comprehensive Cancer Center through individual supporters, corporate partnerships, estates, endowments, foundations and fundraising events.

The Alliance Foundation received a four-out-of-four-stars rating for seven consecutive years from Charity Navigator. This rating demonstrates the Alliance Foundation’s commitment to accountability and transparency.

Educating the NEXT GENERATION
INVESTING IN POPULATION HEALTH AND CANCER PREVENTION

Roswell Park devotes significant resources to research in epidemiologic and population science with the goal of decreasing cancer morbidity and mortality by:

> Identifying factors that affect cancer risk and prognosis, such as health disparities, access to screening and care, and biologic, genetic and lifestyle factors.
> Developing interventions to prevent cancer.

IN THE Past 5 Years, Roswell Park reached more than 65,000 COMMUNITY MEMBERS through evidence-based efforts for people with higher risk of cancer who may not interact with prevention and early detection resources without this continued, purposeful outreach.

From 2018 - 2022, ROSWELL PARK has screened nearly 58,000 PEOPLE for BREAST, LUNG, COLORECTAL and PROSTATE CANCERS.
INTERNATIONAL COLLABORATIONS

Our collaborations enhance cancer research and training programs around the world.

- Concordia Healthcare, Inc.
  - Ontario, Canada
  - Concordia Laboratories, Inc.
  - Luxembourg, Luxembourg
  - F. Hoffman-La Roche Ltd.
  - Basel, Switzerland
  - GPCR Therapeutics, Inc.
  - Seoul, South Korea
  - Helsinn Healthcare SA
  - Lugano, Switzerland
  - Instituto de Biolo
  - Mexico City, Mexico
  - Jagiellonian University
  - Krakow, Poland
  - King Fahad Specialist Hospital
  - Dammam, Saudi Arabia
  - Neomics Co. Ltd.
  - Seoul, South Korea
  - Pinnacle Biologics, Concordia
    International Corp.
  - Ontario, Canada
  - PIQUR Therapeuticsa
  - Basel, Switzerland
  - Semmelweis University*
  - Budapest, Hungary
  - The University of Zurich
  - Zurich, Switzerland
  - University of Pecs Medical School*
  - Pecs, Hungary
  - University of Szeged Faculty*
  - Szeged, Hungary
  - University of Debrecen Medical School
  - Debrecen, Hungary
  - University of Waterloo
  - Ontario, Canada

A network of community hospitals and medical centers in New York and Pennsylvania provides access to Roswell Park physicians, services and clinical trials to patients across the region.
We are proud to be recognized as an LGBTQ+ Healthcare Equality Leader on the Human Rights Campaign Foundation’s Healthcare Equality Index (HEI) 2022 and to be named to Forbes’ 2023 list of America’s Best Employers by State.

Roswell Park is committed to consistent, ongoing and proactive actions that create and support diverse, equitable and inclusive communities both within and outside our center. This work is central to our mission to serve, support and heal our community.

We continue to strive for a more diverse workforce that exceeds the diversity of our region by creating pipelines with local community and education groups to help develop young professionals interested in science and healthcare. We know that our differences are our strengths and that an engaged, diverse workforce is the best way to provide all our patients with the highest level of care.
At Roswell Park, we set the bar higher for quality, safety, and effectiveness of our care. We seek and maintain professional memberships, accreditations, and certifications that demand ongoing quality review and a demonstrated commitment to excellence.

For a list of these, go to: RoswellPark.org/vital-stats